Biosimilar infl iximab CT-Pwy treatment in patients with infl am matory bowel diseases - a one-year, single-centre retrospective study

Gastroenterologie a Hepatologie

Volumn 70, Issue 1, 2016, Pages 27-36

  Hlavaty, T ^a   Krajcovicova, A ^a   Sturdik, I ^a   Letkovsky, J ^a   Koller, T ^a   Toth, J ^a   Huorka, M ^a  

^a UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Biosimilar; Crohn's disease; CT P13; Infliximab; Retrospective study; Therapy; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOSIMILAR AGENT; CT P13; INFLIXIMAB; MESALAZINE; PREDNISONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DERMATITIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MALE; OPPORTUNISTIC INFECTION; PSORIASIS; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS;

EID: 84960910044     PISSN: 18047874     EISSN: 1804803X     Source Type: Journal    
DOI: 10.14735/amgh201627     Document Type: Article

References (43)

1. Mowat C, Cole A, Windsor A et al. Guidelines for the management of infl am matory bowel disease in adults. Gut 2011; 60(5): 571-607. doi: 10.1136/ gut.2010.224154.
2. Present DH, Rutgeerts P, Targan S et al. Infl iximab for the treatment of fi stulas in patients with Crohn's disease. N Eng J Med 1999; 340(18): 1398-1405.
3. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infl iximab for Crohn's dis ease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541-1549.
4. Sands BE, Anderson FH, Bernstein CN et al. Infl iximab maintenance therapy for fistuliz ing Crohn's disease. N Eng J Med 2004; 350(9): 876-885.
5. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infl iximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005; 353(23): 2462-2476.
6. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infl iximab therapy for the treatment of moderate-to- -severe Crohn's disease in children. Gastroenterology 2007; 132(3): 863-873; quiz 1165-1166.
7. Burisch J, Vardi H, Pedersen N et al. Costs and resource utilization for dia gnosis and treatment dur ing the initial year in a European infl am matory bowel disease inception cohort: an ECCO-EpiCom Study. Infl amm Bowel Dis 2015; 21(1): 121-131. doi: 10.1097/ MIB.0000000000000250.
8. European Medicines Agency. Com mittee for Medicinal Products for Human Use (CHMP). As ses sment report: Inflectra (infliximab). [online]. Available from: www. ema.europa.eu/ docs/ en_GB/ document_ library/ EPAR_-_Public_as ses sment_report/ human/002778/ WC500151490.pdf.
9. Rinaudo-Gaujous M, Paul S, Tedesco ED et al. Review article: bio similars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013; 38(8): 914-924. doi: 10.1111/ apt.l2477.
10. Hlavaty T, Letkovsky J. Biosimilars in the therapy of infl am matory bowel diseases. Eur J Gastroenterol Hepatol 2014; 26(6): 581- -587. doi: 10.1097/ MEG.0000000000000 098.
11. Brodszky V, Baji P, Balogh O et al. Budget impact analysis of bio similar infl iximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 (Suppl 1): S65- S71. doi: 10.1007/ s10198-014-0595-3.
12. Kim J, Hong JA, Kudrin A. 5 year budget impact analysis of CT-P13 (Infl iximab) for the treatment of Crohn's disease in UK, Italy and France. J Crohns Colitis 2015; 9 (Suppl 1): S144- S145.
13. Schwaber J, Cohen EP. Human x mouse somatic cell hybrid clone secret ing immunoglobulins of both parental types. Nature 1973; 244(5416): 444-47.
14. Yoo DH, Hrycaj P, Miranda P et al. A randomised, double-blind, paral lel-group study to demonstrate equivalence in effi cacy and safety of CT-P13 compared with in novator infl iximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72(10): 1613-1620. doi: 10.1136/ an nrheumdis-2012-203 090.
15. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-as sociated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48(8): 1754-1762. doi:10.1111/ j.l537-2995.2008.01749.x.
16. Seidl A, Hainzl O, Richter M et al. Tung sten-induced denaturation and aggregation of epoetin alfa dur ing primary packag ing as a cause of im munogenicity. Pharm Res 2012; 29(6): 1454-1467. doi: 10.1007/ s11095-011-0621-4.
17. Park W, Hrycaj P, Jeka S et al. A randomised, double-blind, multicentre, parallel- group, prospective study comparing the pharmacokinetics, safety, and ef ficacy of CT-P13 and in novator infliximab in patients with ankylos ing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72(10): 1605-1612. doi: 10.1136/ an nrheumdis-2012-203091.
18. Danese S, Gomol lon F. Govern ing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of infl am matory bowel disease (IBD). J Crohns Colitis 2013; 7(7): 586-589. doi: 10.1016/ j. crohns.2013.03.011.
19. Gecse KB, Khan na R, van den Brink GR et al. Biosimilars in IBD: hope or expectation? Gut 2013; 62(6): 803-807. doi: 10.1136/ gutjnl-2012-303824.
20. Silverberg MS, Satsangi J, Ahmad T et al. Toward an integrated clinical, molecular and serological clas sifi cation of infl ammatory bowel disease: report of a Work ing Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A):5A-36A.
21. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1(8167): 514.
22. Vermeire S, Schreiber S, Sandborn WJ et al. Cor relation between the Crohn's disease activity and Harvey-Bradshaw indices in as ses s ing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8(4): 357-363. doi: 10.1016/ j.cgh.2010.01.001.
23. Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, procto sigmoiditis, and proctitis. Gastroenterology 1987; 92(6): 1894-1898.
24. Irvine EJ, Zhou Q, Thompson AK. The Short Inflam matory Bowel Disease Question naire: a quality of life instrument for com munity physicians managing inflam matory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996; 91(8): 1571-1578.
25. Lewis JD, Chuai S, Nes sel L et al. Use of the noninvasive components of the Mayo score to as sess clinical response in ulcerative colitis. Infl amm Bowel Dis2008; 14(12): 1660-1666. doi: 10.1002/ ibd.20520.
26. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Eng J Med 1997; 337(15): 1029-1035.
27. Orlando A, Colombo E, Kohn A et al. Infliximab in the treatment of Crohn's dis ease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37(8): 577-583.
28. Ricart E, Panaccione R, Loftus EV et al. Infl iximab for Crohn's disease in clinical practice at the Mayo Clinic: the fi rst 100 patients. Am J Gastroenterol 2001; 96(3): 722-729.
29. Far rell RJ, Shah SA, Lodhavia PJ et al. Clinical experience with infliximab therapy in 100 patients with Crohn's dis ease. Am J Gastroenterol 2000; 95(12): 3490-3497.
30. Seminerio JL, Loftus EV Jr, Colombel JF et al. Infl iximab for Crohn's disease: the fi rst 500 patients fol lowed up through 2009. Dig Dis Sci 2013; 58(3): 797-806. doi: 10.1007/ sl0620-012-2405-z.
31. Fer rante M, Vermeire S, Katsanos KH et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007; 13(2): 123-128.
32. Oussalah A, Evesque L, Laharie D et al. A multicenter experience with infl iximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105(12): 2617-2625. doi: 10.1038/ ajg.2010.345.
33. Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A et al. Open-label infl iximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008; 55(86-87): 1609-1614.
34. Rutgeerts P, D'Haens G, Targan S et al. Ef ficacy and safety of retreatment with anti-tumor necrosis factor antibody (infl iximab) to maintain remis sion in Crohn's disease. Gastroenterology 1999; 117(4): 761-769.
35. Armuzzi A, Pugliese D, Danese S et al. Infliximab in steroid-dependent ulcerative colitis: ef fectiveness and predictors of clinical and endoscopic remis sion. Inflamm Bowel Dis 2013; 19(5): 1065- -1072. doi: 10.1097/ MIB.0b013e3182802 909.
36. Schnitzler F, Fidder H, Fer rante M et al. Long-term outcome of treatment with infl iximab in 614 patients with Crohn's dis ease: results from a single-centre cohort. Gut 2009; 58(4): 492-500. doi: 10.1136/ gut. 2008.155812
37. Teshima CW, Thompson A, Dhanoa L et al. Long-term response rates to infl iximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009; 23(5): 348-352.
38. Kang Y-S, Moon HH, Lee SE et al. Clin ical experience of the use of CT-P13, a bio similar to infl iximab in patients with inflam matory bowel disease: a case series. Dig Dis Sci 2015; 60(4): 951-956. doi: 10.1007/ sl0620-014-3392-z.
39. Jung YS, Park DI, Kim YH et al. Efficacy and safety of CT-P13, a bio similar of infliximab, in patients with inflam matory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol 2015. doi: 10.1111/ jgh.l2997.
40. Jarzbicka D, Ptocek A, Sieczkowska J et al. First observations of the use of biosimilar infliximab for treatment of ulcerative colitis in paediatric population. J Crohns Colitis 2015; 9 (Suppl 1): S307 S308.
41. Sieczkowska J, Banaszkiewicz A, PtocekA et al. As ses sment of safety and efficacy of bio similar infl iximab in children with Crohn disease: a preliminary report. J Crohns Colitis 2015; 9 (Suppl 1): S295.
42. Jarzebicka D, Banaszkiewicz A, Ptocek A et al. Preliminary as ses sment of efficacy and safety of switch ing between originator and bio similar infliximab in paediatric Crohn disease patients. J Crohns Colitis 2015; 9 (Suppl 1): S224- S225.
43. Gecse K, Farkas K,Lovasz B et al. Biosimilar infl iximab in infl am matory bowel diseases: fi rst interim Results from a prospective nationwide observational cohort. J Crohns Colitis 2015; 9 (Suppl 1): S234- S235.